The Patented Medicine Prices Review Board (PMPRB) has released its 4th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2016/17. The report was prepared as part of the National Prescription Drug Utilization Information System (NPDUIS), and examines public drug plan expenditures in Canada, including analyzing the main factors that drive annual changes in prescription drug expenditures.
PMPRB has also released the 2017 Supplement to the Market Intelligence Report, Biologic Response Modifier Agents, 2015, both produced under the NPDUIS initiative. Using data from 2017, the Supplement provides updated information for market trends analyzed in the original report, which focuses on certain biologics that the report refers to as “biologic disease-modifying antirheumatic drugs or biologic DMARDs.”
Lastly, the PMPRB has released its 2017 Annual Report. The 2017 Annual Report includes a review of the PMPRB’s regulatory activities, analyses of sales and price trends of pharmaceuticals, as well as an overview of NPDUIS and analysis of research and development expenditures. On August 22, 2018, the Minister of Health tabled the 2017 Annual Report with the Clerks of the House of Commons and the Senate.
Related Publications & Articles
-
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Minister of Health proposes legislation for first phase of national universal pharmacare
On February 29, 2024, the Minister of Health announced the introduction of Bill C-64, An Act respecting pharmacare (Pharmacare Act).Read More -
PMPRB releases 2022 Annual Report and March 2024 NEWSletter
On February 16, 2024, the Minister of Health tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB).Read More